POINT: Should Triple Inhaled Therapy Be Considered in All Patients With Group E COPD? Yes.

Chest

Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX. Electronic address:

Published: July 2024

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chest.2024.03.029DOI Listing

Publication Analysis

Top Keywords

point triple
4
triple inhaled
4
inhaled therapy
4
therapy considered
4
considered patients
4
patients group
4
group copd?
4
point
1
inhaled
1
therapy
1

Similar Publications

Purpose: Trophoblast cell-surface antigen 2 (Trop2) is overexpressed in various solid tumors and contributes to tumor progression, while its expression remains low in normal tissues. Trop2-targeting antibody-drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen. Leveraging the enhanced specificity of ADCs, we conducted the first immunoPET imaging study of Trop2 expression in gastric cancer (GC) and triple-negative breast cancer (TNBC) models using Zr-labeled Trodelvy ([Zr]Zr-DFO-Trodelvy).

View Article and Find Full Text PDF

Ectopic breast tissue (EBT) represents a congenital anomaly caused by incomplete regression of mammary ridges at the time of embryonic development. Typically, EBT presents along the mammary line, although usually in the axillary region, it has been located occasionally in unusual sites such as the vulva. Though relatively rare, it is generally subject to a wide range of pathologies that afflict normal breast tissue, encompassing both benign and malignant transformations.

View Article and Find Full Text PDF

Enzymatic asymmetric synthesis of l-phenylglycine by amino acid dehydrogenases has potential for industrial applications; however, this is hindered by their low catalytic efficiency toward high-concentration substrates. We identified and characterized a novel leucine dehydrogenase (LeuDH) with a high catalytic efficiency for benzoylformic acid via directed metagenomic approaches. Further, we obtained a triple-point mutant LeuDH-EER (D332E/G333E/L334R) with improved stability and catalytic efficiency through the rational design of distal loop 13.

View Article and Find Full Text PDF

Effects of Elexacaftor-Tezacaftor-Ivacaftor on Nasal and Sinus Symptoms in Children With Cystic Fibrosis.

Pediatr Pulmonol

January 2025

Hôpital Femme Mère Enfant, Hospices Civils de Lyon, 59 Boulevard Pinel, Lyon, France.

Background: New CFTR Modulator triple therapy Elexacaftor-Ivacaftor-Tezacaftor (ETI) prove efficacy in pulmonary outcomes. However, its impact on nasal sinus symptoms in children has not been specifically studied. The aim of this study is to evaluate the impact of this therapy on nasal sinus symptomatology in children aged 6-12 years.

View Article and Find Full Text PDF

: Among breast cancer molecular types, HER2 positive and triple negative (TN) subtypes have the highest likelihood of pathological complete response (pCR), which is a surrogate marker for reduced recurrence and improved patient survival after neoadjuvant systemic treatment (NST). Preoperative pathological identification of these exceptional responders is a new era. Therefore, we aimed to determine the accuracy of trucut biopsy in identifying the exceptional responders in selected molecular subtypes of breast cancer patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!